Statins as potential therapeutic agents in multiple sclerosis

被引：11

作者：

Stüve O. ^{[1
]}

Prod'homme T. ^{[1
]}

Youssef S. ^{[1
]}

Dunn S. ^{[1
]}

Neuhaus O. ^{[1
]}

Weber M. ^{[1
]}

Hartung H.-P. ^{[1
]}

Steinman L. ^{[1
]}

Zamvil S.S. ^{[1
]}

机构：

[1] Department of Neurology, Univ. of California, San Francisco, San Francisco, CA 94143-0114

来源：

Current Neurology and Neuroscience Reports | 2004年 / 4卷 / 3期

基金：

美国国家卫生研究院;

关键词：

Multiple Sclerosis; Simvastatin; Atorvastatin; Experimental Autoimmune Encephalomyelitis; Major Histocompatibility Complex Class;

D O I：

10.1007/s11910-004-0044-2

中图分类号：

学科分类号：

摘要：

3-Hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (ie, statins) are oral cholesterol-lowering drugs. Statins are well tolerated and have an excellent safety record. These agents competitively inhibit HMG CoA reductase, which is the enzyme that catalyzes the conversion of HMG CoA to L-mevalonate. Although L-mevalonate is a key intermediate in cholesterol synthesis, several of its metabolites are involved in post-translational modification of specific proteins involved in cell proliferation and differentiation. Thus, independent of their cholesterol-reducing properties, statins have important pleiotropic biologic effects. Recent reports indicate that statins have anti-inflammatory and neuroprotective properties. Whether statins will be of clinical benefit for patients with multiple sclerosis and other neurodegenerative diseases of the central nervous system will only be known after they are evaluated in prospective randomized clinical trials. Copyright © 2004 by Current Science Inc.

引用

页码：237 / 244

页数：7

共 91 条

[1]

Anderson D.W., Ellenberg J.H., Leventhal C.M., Et al., Revised estimate of the prevalence of multiple sclerosis in the United States, Ann. Neurol., 31, pp. 333-336, (1992)

[2]

Genain C.P., Cannella B., Hauser S.L., Raine C.S., Identification of autoantibodies associated with myelin damage in multiple sclerosis, Nat. Med., 5, pp. 170-175, (1999)

[3]

Genain C.P., Nguyen M.H., Letvin N.L., Et al., Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate, J. Clin. Invest., 96, pp. 2966-2974, (1995)

[4]

Weiner H.L., Hauser S.L., Neuroimmunology I: Immunoregulation in neurological disease, Ann. Neurol., 11, pp. 437-449, (1982)

[5]

Ebers G., Pathy D.W., The major histocompatibility complex, the immune system and multiple sclerosis, Clin. Neurol. Neurosurg., 81, pp. 69-86, (1979)

[6]

Arnason B.G., Relevance of experimental allergic encephalomyelitis to multiple sclerosis, Neurol. Clin., 1, pp. 765-782, (1983)

[7]

Martin R., McFarland H.F., McFarlin D.E., Immunological aspects of demyelinating diseases, Annu. Rev. Immunol., 10, pp. 153-187, (1992)

[8]

Raine C.S., Biology of disease. Analysis of autoimmume demyelination: Its impact upon multiple sclerosis, Lab. Invest., 50, pp. 608-635, (1984)

[9]

Zamvil S.S., Soos J.M., Weiner H.L., Pathogenesis and treatment of central nervous system demyelinating disease, Rev. Neurol. (Paris), 154, pp. 573-575, (1998)

[10]

Stuve O., Cree B.C., von Budingen H.C., Et al., Approved and future pharmacotherapies for multiple sclerosis, Neurologist, 8, pp. 290-301, (2002)

← 1 2 3 4 5 6 7 8 9 10 →